Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
30 oct. 2024 16h30 HE
|
Cardiff Oncology, Inc.
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis...
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
08 août 2024 16h05 HE
|
Cardiff Oncology, Inc.
- Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP...
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update
01 août 2024 16h05 HE
|
Cardiff Oncology, Inc.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology to Present at the Jefferies Healthcare Conference
29 mai 2024 16h05 HE
|
Cardiff Oncology, Inc.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology to Present at Upcoming Investor Conferences in May
13 mai 2024 16h05 HE
|
Cardiff Oncology, Inc.
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
02 mai 2024 16h05 HE
|
Cardiff Oncology, Inc.
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated...
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
25 avr. 2024 16h05 HE
|
Cardiff Oncology, Inc.
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a...
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
08 avr. 2024 16h05 HE
|
Cardiff Oncology, Inc.
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor...
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
06 mars 2024 16h05 HE
|
Cardiff Oncology, Inc.
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
29 févr. 2024 16h07 HE
|
Cardiff Oncology, Inc.
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data...